FDA promising carrots and sticks for gene, cell therapy developers

Looking past the shutdown, FDA Tuesday outlined policies it is taking to ramp up regulatory support for cell and gene therapy products. It is also threatening to crack down on investigators and clinicians who refuse to submit cell therapies to premarket review.

The agency plans to add about 50 clinical reviewers dedicated to oversight

Read the full 541 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE